References

10.1056/nejmoa1003466

10.1056/nejmoa1003466 · External reference

10.1200/jco.2011.38.4032

10.1200/jco.2011.38.4032 · External reference

10.1097/cji.0b013e318156e47e

10.1097/cji.0b013e318156e47e · External reference

10.1073/pnas.0605251103

10.1073/pnas.0605251103 · External reference

10.1038/nrc3239

10.1038/nrc3239 · External reference

Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists

10.1158/2326-6066.cir-14-0075 · 2014 · External reference

A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells

10.1182/blood-2007-03-081646 · 2008 · External reference

10.1128/mcb.25.21.9543-9553.2005

10.1128/mcb.25.21.9543-9553.2005 · External reference

10.1038/35105024

10.1038/35105024 · External reference

10.1016/s1074-7613(01)00259-x

10.1016/s1074-7613(01)00259-x · External reference

CTLA-4 is a second receptor for the B cell activation antigen B7

10.1084/jem.174.3.561 · 1991 · External reference

10.1126/science.1160062

10.1126/science.1160062 · External reference

10.1111/j.1600-065x.2010.00923.x

10.1111/j.1600-065x.2010.00923.x · External reference

10.1002/j.1460-2075.1992.tb05481.x

10.1002/j.1460-2075.1992.tb05481.x · External reference

10.1111/j.1600-065x.2009.00767.x

10.1111/j.1600-065x.2009.00767.x · External reference

10.1038/nm863

10.1038/nm863 · External reference

10.1038/nm730

10.1038/nm730 · External reference

10.1165/rcmb.2004-0129oc

10.1165/rcmb.2004-0129oc · External reference

10.4049/jimmunol.169.7.3581

10.4049/jimmunol.169.7.3581 · External reference

10.1038/bjc.2014.348

10.1038/bjc.2014.348 · External reference

The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer

2014 · External reference

10.1146/annurev.immunol.26.021607.090331

10.1146/annurev.immunol.26.021607.090331 · External reference

10.1016/1074-7613(95)90125-6

10.1016/1074-7613(95)90125-6 · External reference

10.1126/science.270.5238.985

10.1126/science.270.5238.985 · External reference

10.1016/j.cellimm.2012.07.001

10.1016/j.cellimm.2012.07.001 · External reference

10.1002/pros.21020

10.1002/pros.21020 · External reference

10.1038/nri2326

10.1038/nri2326 · External reference

Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages

1997 · External reference

10.1126/science.271.5256.1734

10.1126/science.271.5256.1734 · External reference

10.1056/nejmoa1104621

10.1056/nejmoa1104621 · External reference

10.1056/nejmoa1200690

10.1056/nejmoa1200690 · External reference

10.1016/s1470-2045(13)70551-5

10.1016/s1470-2045(13)70551-5 · External reference

10.1200/jco.2012.48.3685

10.1200/jco.2012.48.3685 · External reference

10.1056/nejmoa1200694

10.1056/nejmoa1200694 · External reference

Unresolved reference

2014 · External reference

Historical overview of immunological tolerance

10.1101/cshperspect.a006908 · 2012 · External reference

10.1056/nejmra1205750

10.1056/nejmra1205750 · External reference

10.1038/nrd2638

10.1038/nrd2638 · External reference

10.1038/nature13085

10.1038/nature13085 · External reference

10.1038/414916a

10.1038/414916a · External reference

Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides

10.1152/ajpcell.1993.265.3.c577 · 1993 · External reference

The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine

1997 · External reference

Molecular characterization of recombinant human adenosine receptors

10.1002/(sici)1098-2299(199611/12)39:3/4<243::aid-ddr3>3.0.co;2-r · 1996 · External reference

10.1080/08916930701464939

10.1080/08916930701464939 · External reference

Adenosine receptors and cancer

10.1007/978-3-540-89615-9_14 · 2009 · External reference

10.1158/2159-8290.cd-14-0341

10.1158/2159-8290.cd-14-0341 · External reference

10.1186/ar1914

10.1186/ar1914 · External reference

Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease

10.1053/j.gastro.2005.05.032 · 2005 · External reference

A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis

10.1086/386311 · 2004 · External reference

Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice

10.1172/jci60214 · 2012 · External reference

10.1053/j.gastro.2008.10.037

10.1053/j.gastro.2008.10.037 · External reference

Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia

1987 · External reference

10.1158/1078-0432.ccr-13-0545

10.1158/1078-0432.ccr-13-0545 · External reference

CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth

10.1155/2012/485156 · 2012 · External reference

Adenosine, an endogenous anti-inflammatory agent

10.1152/jappl.1994.76.1.5 · 1985 · External reference

Adenosine receptor subtypes: characterization and therapeutic regulation

10.1146/annurev.pa.35.040195.003053 · 1995 · External reference

10.1158/0008-5472.can-06-4249

10.1158/0008-5472.can-06-4249 · External reference

The A2aR adenosine receptor controls cytokine production in iNKT cells

10.1002/eji.200939897 · 2010 · External reference

Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition

10.4049/jimmunol.178.7.4240 · 2007 · External reference

10.1084/jem.20062512

10.1084/jem.20062512 · External reference

10.1007/s00262-011-1155-7

10.1007/s00262-011-1155-7 · External reference

10.1158/0008-5472.can-13-3581

10.1158/0008-5472.can-13-3581 · External reference

10.1084/jem.20130249

10.1084/jem.20130249 · External reference

10.1111/j.1600-065x.1995.tb00680.x

10.1111/j.1600-065x.1995.tb00680.x · External reference

Effects of extracellular ATP and adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptor

10.4049/jimmunol.158.11.5095 · 1997 · External reference

Ecto-ATPase activity in cytolytic T-lymphocytes. Protection from the cytolytic effects of extracellular ATP

10.1016/s0021-9258(19)40234-2 · 1990 · External reference

10.1111/j.1600-065x.1998.tb01574.x

10.1111/j.1600-065x.1998.tb01574.x · External reference

Two novel families of ectonucleotidases: molecular structures, catalytic properties and a search for function

10.1016/s0165-6147(99)01293-6 · 1999 · External reference

10.1182/blood-2008-02-136325

10.1182/blood-2008-02-136325 · External reference

Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells: involvement of protein kinase A isozyme I (PKA I)

10.1385/ir:36:1:91 · 2006 · External reference

10.1182/blood-2003-06-1959

10.1182/blood-2003-06-1959 · External reference

Apparent involvement of the A(2A) subtype adenosine receptor in the anti-inflammatory interactions of CGS 21680, cyclopentyladenosine, and IB-MECA with human neutrophils

10.1016/s0006-2952(00)00414-7 · 2000 · External reference

10.1165/rcmb.2008-0168oc

10.1165/rcmb.2008-0168oc · External reference

10.1073/pnas.1308209110

10.1073/pnas.1308209110 · External reference

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor

10.1158/0008-5472.can-14-0957 · 2014 · External reference

Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model

2014 · External reference

10.1158/0008-5472.can-10-4246

10.1158/0008-5472.can-10-4246 · External reference

10.1073/pnas.1222251110

10.1073/pnas.1222251110 · External reference

10.1155/2014/460654

10.1155/2014/460654 · External reference

10.1073/pnas.0908801107

10.1073/pnas.0908801107 · External reference

Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced anti-tumor T cell responses

10.1158/2326-6066.cir-14-0211 · 2015 · External reference

Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued

10.1007/s40263-014-0161-7 · 2014 · External reference

10.1053/j.seminoncol.2010.09.010

10.1053/j.seminoncol.2010.09.010 · External reference

Dendritic cells tolerized with adenosine A(2)AR agonist attenuate acute kidney injury

10.1172/jci63170 · 2012 · External reference

10.1158/0008-5472.can-13-3583

10.1158/0008-5472.can-13-3583 · External reference

Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors

10.1189/jlb.3a0513-302rr · 2014 · External reference

10.1038/nrd3626

10.1038/nrd3626 · External reference

10.1146/annurev-immunol-032712-100008

10.1146/annurev-immunol-032712-100008 · External reference

Trial Watch: chemotherapy with immunogenic cell death inducers

10.4161/onci.27878 · 2014 · External reference

Autophagy in non-small cell lung carcinogenesis: a positive regulator of antitumor immunosurveillance

10.4161/auto.27643 · 2014 · External reference

10.1038/cdd.2013.75

10.1038/cdd.2013.75 · External reference

Cutting edge: critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis

10.4049/jimmunol.177.5.2765 · 2006 · External reference

Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis

10.2217/imt.13.154 · 2014 · External reference

10.1172/jci45559

10.1172/jci45559 · External reference

10.1158/0008-5472.can-12-0420

10.1158/0008-5472.can-12-0420 · External reference

The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma

2015 · External reference

10.1002/eji.201041292

10.1002/eji.201041292 · External reference

A2B adenosine receptor blockade inhibits growth of prostate cancer cells

10.1007/s11302-012-9350-3 · 2013 · External reference

10.4049/jimmunol.1101845

10.4049/jimmunol.1101845 · External reference